You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 11, 2025

XIIDRA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Xiidra, and when can generic versions of Xiidra launch?

Xiidra is a drug marketed by Bausch And Lomb Inc and is included in one NDA. There are eleven patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and fifty-four patent family members in twenty-five countries.

The generic ingredient in XIIDRA is lifitegrast. Three suppliers are listed for this compound. Additional details are available on the lifitegrast profile page.

DrugPatentWatch® Generic Entry Outlook for Xiidra

Xiidra was eligible for patent challenges on July 11, 2020.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (lifitegrast), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

< Available with Subscription >

  Try for Free

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for XIIDRA?
  • What are the global sales for XIIDRA?
  • What is Average Wholesale Price for XIIDRA?
Drug patent expirations by year for XIIDRA
Drug Prices for XIIDRA

See drug prices for XIIDRA

Recent Clinical Trials for XIIDRA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Novartis PharmaceuticalsPhase 4
State University of New York College of OptometryPhase 4
Bucci Laser Vision InstitutePhase 4

See all XIIDRA clinical trials

Paragraph IV (Patent) Challenges for XIIDRA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
XIIDRA Ophthalmic Solution lifitegrast 5% 208073 4 2020-07-13

US Patents and Regulatory Information for XIIDRA

XIIDRA is protected by eleven US patents.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb Inc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Bausch And Lomb Inc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y ⤷  Try for Free
Bausch And Lomb Inc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Bausch And Lomb Inc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y Y ⤷  Try for Free
Bausch And Lomb Inc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for XIIDRA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch And Lomb Inc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 ⤷  Try for Free ⤷  Try for Free
Bausch And Lomb Inc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 ⤷  Try for Free ⤷  Try for Free
Bausch And Lomb Inc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 ⤷  Try for Free ⤷  Try for Free
Bausch And Lomb Inc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 ⤷  Try for Free ⤷  Try for Free
Bausch And Lomb Inc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for XIIDRA

When does loss-of-exclusivity occur for XIIDRA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 08317473
Patent: Compositions and methods for treatment of diabetic retinopathy
Estimated Expiration: ⤷  Try for Free

Canada

Patent: 02984
Patent: COMPOSITIONS ET PROCEDES POUR LE TRAITEMENT DE LA RETINOPATHIE DIABETIQUE (COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY)
Estimated Expiration: ⤷  Try for Free

Patent: 58665
Patent: COMPOSITIONS ET PROCEDES POUR LE TRAITEMENT DE LA RETINOPATHIE DIABETIQUE (COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY)
Estimated Expiration: ⤷  Try for Free

Patent: 05972
Patent: COMPOSITIONS ET PROCEDES POUR LE TRAITEMENT DE LA RETINOPATHIE DIABETIQUE (COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY)
Estimated Expiration: ⤷  Try for Free

China

Patent: 1873797
Patent: Compositions and methods for treatment of diabetic retinopathy
Estimated Expiration: ⤷  Try for Free

Patent: 2056485
Patent: Topical LFA-1 antagonists for use in localized treatment of immune related disorders
Estimated Expiration: ⤷  Try for Free

Patent: 2065694
Patent: Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders
Estimated Expiration: ⤷  Try for Free

Patent: 2065893
Patent: Delivery of LFA-1 antagonists to the gastrointestinal system
Estimated Expiration: ⤷  Try for Free

Patent: 5943534
Patent: 用于局部治疗免疫相关疾病的局部LFA-1拮抗剂 (Topical LFA-1 antagonists for use in localized treatment of immune related disorders)
Estimated Expiration: ⤷  Try for Free

European Patent Office

Patent: 09371
Patent: COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE LA RÉTINOPATHIE DIABÉTIQUE (COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY)
Estimated Expiration: ⤷  Try for Free

Patent: 65124
Patent: ANTAGONISTES DE LFA-1 SOUS FORME D'AÉROSOL UTILISÉS EN TRAITEMENT LOCALISÉ DE TROUBLES DE NATURE IMMUNITAIRE (AEROSOLIZED LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS)
Estimated Expiration: ⤷  Try for Free

Patent: 65125
Patent: ANTAGONISTES DE LFA-1 TOPIQUES UTILISÉS DANS LE TRAITEMENT LOCALISÉ DE TROUBLES DE NATURE IMMUNITAIRE (TOPICAL LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS)
Estimated Expiration: ⤷  Try for Free

Patent: 76508
Patent: ADMINISTRATION D'ANTAGONISTES DE LFA-1 AU SYSTÈME GASTRO-INTESTINAL (DELIVERY OF LFA-1 ANTAGONISTS TO THE GASTROINTESTINAL SYSTEM)
Estimated Expiration: ⤷  Try for Free

Patent: 67886
Patent: COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE L'OEDÈME MACULAIRE (COMPOSITIONS AND METHODS FOR TREATMENT OF MACULAR EDEMA)
Estimated Expiration: ⤷  Try for Free

Patent: 32444
Patent: ANTAGONISTES LFA-1 TOPIQUES POUR UNE UTILISATION DANS LE TRAITEMENT LOCALISÉ DE TROUBLES IMMUNITAIRES ASSOCIÉS (TOPICAL LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS)
Estimated Expiration: ⤷  Try for Free

Patent: 97775
Patent: COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE LA RÉTINOPATHIE DIABÉTIQUE (COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY)
Estimated Expiration: ⤷  Try for Free

Japan

Patent: 08037
Estimated Expiration: ⤷  Try for Free

Patent: 11500683
Estimated Expiration: ⤷  Try for Free

Patent: 11516607
Estimated Expiration: ⤷  Try for Free

Patent: 11518155
Estimated Expiration: ⤷  Try for Free

Patent: 11521896
Estimated Expiration: ⤷  Try for Free

Patent: 14132032
Patent: TOPICAL LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS
Estimated Expiration: ⤷  Try for Free

Patent: 14132033
Patent: AEROSOLIZED LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS
Estimated Expiration: ⤷  Try for Free

Patent: 14133751
Patent: DELIVERY OF LFA-1 ANTAGONISTS TO GASTROINTESTINAL SYSTEM
Estimated Expiration: ⤷  Try for Free

Patent: 14221808
Patent: 糖尿病性網膜症の治療のための組成物及び方法 (COMPOSITION AND METHOD FOR TREATMENT OF DIABETIC RETINOPATHY)
Estimated Expiration: ⤷  Try for Free

Patent: 16128515
Patent: 免疫関連障害の局所治療に使用するためのエアゾール化LFA−1アンタゴニスト (AEROSOLIZED LFA-1 ANTAGONIST TO BE USED FOR TOPICAL TREATMENT OF IMMUNE RELATED DISORDERS)
Estimated Expiration: ⤷  Try for Free

Patent: 16153432
Patent: 胃腸系へのLFA−1アンタゴニストの送達 (DELIVERY OF LFA-1 ANTAGONISTS TO GASTROINTESTINAL SYSTEM)
Estimated Expiration: ⤷  Try for Free

Patent: 17141310
Patent: 免疫関連障害の局所治療に使用するためのエアゾール化LFA−1アンタゴニスト (AEROSOLIZED LFA-1 ANTAGONIST TO BE USED FOR TOPICAL TREATMENT OF IMMUNE RELATED DISORDERS)
Estimated Expiration: ⤷  Try for Free

Patent: 18127485
Patent: 胃腸系へのLFA−1アンタゴニストの送達 (DELIVERY OF LFA-1 ANTAGONISTS TO GASTROINTESTINAL SYSTEM)
Estimated Expiration: ⤷  Try for Free

Patent: 20023546
Patent: 胃腸系へのLFA−1アンタゴニストの送達 (DELIVERY OF LFA-1 ANTAGONISTS TO GASTROINTESTINAL SYSTEM)
Estimated Expiration: ⤷  Try for Free

Mexico

Patent: 10004281
Patent: COMPOSICIONES Y METODOS PARA EL TRATAMIENTO DE LA RETINOPATIA DIABETICA. (COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY.)
Estimated Expiration: ⤷  Try for Free

Spain

Patent: 30406
Estimated Expiration: ⤷  Try for Free

Patent: 63703
Estimated Expiration: ⤷  Try for Free

Patent: 30024
Estimated Expiration: ⤷  Try for Free

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XIIDRA around the world.

Country Patent Number Title Estimated Expiration
Canada 2544678 MODULATORS OF CELLULAR ADHESION ⤷  Try for Free
Denmark 1881823 ⤷  Try for Free
European Patent Office 1881823 COMPOSITIONS ET PROCEDES POUR LE TRAITEMENT DES TROUBLES OCULAIRES (COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS) ⤷  Try for Free
World Intellectual Property Organization (WIPO) 2005044817 ⤷  Try for Free
World Intellectual Property Organization (WIPO) 2014100135 ⤷  Try for Free
>Country >Patent Number >Title >Estimated Expiration

Market Dynamics and Financial Trajectory for Xiidra

Introduction to Xiidra

Xiidra, also known as lifitegrast, is a prescription eye drop used to treat the signs and symptoms of dry eye disease. It has been a significant player in the ophthalmology market, particularly in the dry eye syndrome treatment segment.

Market Dominance of Xiidra

As of 2024, the Xiidra segment dominated the dry eye syndrome treatment market, capturing a revenue share of 8.52%. This dominance can be attributed to several factors, including its affordability, easy availability, and effectiveness in producing artificial tears. The drug's strategic positioning and marketing efforts by its manufacturers have also played a crucial role[1].

Acquisition and Market Impact

In a significant move, Bausch + Lomb acquired Xiidra from Novartis in September 2023. This acquisition was part of Novartis' broader strategy to focus on prioritized therapeutic areas with high disease burdens and greater growth potential. The transaction, valued at up to $2.5 billion, included $1.75 billion in upfront cash and additional milestone payments based on sales performance. This acquisition has bolstered Bausch + Lomb's dry eye disease portfolio and is expected to expand the market penetration of Xiidra[4].

Financial Performance

The acquisition of Xiidra has had a substantial impact on Bausch + Lomb's financial performance. In the fourth quarter of 2023, the pharmaceuticals segment revenue for Bausch + Lomb increased by 67% compared to the same period in 2022, primarily due to the acquisition of Xiidra, along with higher sales of other products like Vyzulta and MIEBO. For the full year of 2023, the segment revenue increased by 23%, excluding the unfavorable impact of foreign exchange[2].

Revenue Growth

Prior to the acquisition, Xiidra's sales had shown some decline. For instance, in the second quarter of 2023, Xiidra sales were $96 million, down by 24% on both a reported and constant currency basis. However, post-acquisition, the drug is expected to see significant growth. Bausch + Lomb's strategic initiatives and expanded market reach are anticipated to drive Xiidra's revenue growth over the forecast period[1][5].

Competitive Landscape

The dry eye syndrome treatment market is competitive, with other drugs like Tyrvaya (varenicline solution) also gaining traction. Tyrvaya, for example, is expected to grow at a lucrative CAGR, driven by research and development and its expanding availability. However, Xiidra's established market presence and the backing of Bausch + Lomb's resources are likely to maintain its market leadership[1].

Impact of Generic Competition

While Xiidra's market position is strong, the broader pharmaceutical landscape is affected by generic competition. The divestment of Xiidra from Novartis was part of a strategy to mitigate the impact of generic competition on other products. For instance, Novartis faced erosion in sales due to generic competition for drugs like Gilenya and Lucentis. However, Xiidra's unique positioning and the lack of generic alternatives currently make it less vulnerable to such competition[3][4].

Future Outlook

The dry eye disease market is projected to grow significantly, with estimates suggesting it will reach $5.2 billion by 2034. Xiidra, with its established presence and the support of Bausch + Lomb, is well-positioned to capitalize on this growth. The drug's effectiveness, combined with strategic marketing and distribution efforts, is expected to drive its revenue and market share in the coming years[4].

Strategic Initiatives

Bausch + Lomb's acquisition of Xiidra is part of a broader strategy to strengthen its ophthalmology portfolio. The company has been focusing on expanding its market penetration through strategic acquisitions and product launches. For example, the launch of MIEBO and higher sales of Vyzulta have contributed to the company's overall revenue growth. These initiatives are expected to continue driving Xiidra's success in the market[2].

Industry Expert Insights

Industry experts highlight the importance of innovative treatments in the ophthalmology sector. "The acquisition of Xiidra by Bausch + Lomb is a significant move that underscores the company's commitment to addressing the growing need for effective dry eye treatments," said a pharmaceutical industry analyst. "With the right strategic initiatives, Xiidra is poised to continue its market dominance."

Illustrative Statistics

  • Revenue Share: Xiidra held an 8.52% revenue share in the dry eye syndrome treatment market in 2024[1].
  • Acquisition Value: The acquisition of Xiidra by Bausch + Lomb was valued at up to $2.5 billion[4].
  • Revenue Growth: Bausch + Lomb's pharmaceuticals segment revenue increased by 67% in the fourth quarter of 2023, largely due to the acquisition of Xiidra[2].
  • Market Size: The dry eye disease market is estimated to reach $5.2 billion by 2034[4].

Key Takeaways

  • Xiidra dominates the dry eye syndrome treatment market with a significant revenue share.
  • The acquisition by Bausch + Lomb is expected to drive further growth and market penetration.
  • The drug's effectiveness and affordability are key factors in its market success.
  • Strategic initiatives by Bausch + Lomb, including product launches and acquisitions, support Xiidra's financial trajectory.
  • The dry eye disease market is projected to grow substantially, benefiting Xiidra's future outlook.

FAQs

Q: What is Xiidra used for? A: Xiidra, also known as lifitegrast, is a prescription eye drop used to treat the signs and symptoms of dry eye disease.

Q: Who acquired Xiidra from Novartis? A: Bausch + Lomb acquired Xiidra from Novartis in September 2023.

Q: What was the value of the acquisition? A: The acquisition was valued at up to $2.5 billion, including $1.75 billion in upfront cash and additional milestone payments based on sales performance.

Q: How has the acquisition impacted Bausch + Lomb's financial performance? A: The acquisition has significantly increased Bausch + Lomb's pharmaceuticals segment revenue, with a 67% increase in the fourth quarter of 2023 compared to the same period in 2022.

Q: What is the projected growth of the dry eye disease market? A: The dry eye disease market is estimated to reach $5.2 billion by 2034, driven by increased demand for effective treatments like Xiidra.

Sources

  1. Grand View Research - Dry Eye Syndrome Treatment Market Size Report, 2030
  2. Business Wire - Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 Guidance
  3. Novartis - Q2 2024 Interim Financial Report – Supplementary Data
  4. BioSpace - Dry Eye Disease Market Size Estimated to Reach USD 5.2 Billion by 2034
  5. Novartis - Q2 2023 Condensed Financial Report – Supplementary Data

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.